TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05715931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab, 240 mg IV infusion on Day 1 of each 21 day cycle for 3 cycles prior to surgery and 3 cycles after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab, 8 mg/kg IV loading dose at 1st administration and then 6 mg/kg IV on Day 1 of each 21 day cycle for 3 cycles before surgery and 3 cycles after surgery. The first administration of trastuzumab after surgery should also be given at the loading dose of 8 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT)
Description: Pre-operative treatment 4 cycles and post-operative treatment 4 cycles:~Docetaxel 50 mg/m², IV on day 1 of each 14 day cycle; Oxaliplatin 85 mg/m² , IV on day 1 of each 14 day cycle; Leucovorin 200 mg/m² or Levoleucovorin 100 mg/m², IV on day 1 of each 14 day cycle; 5-FU 2600 mg/m², IV over 24 h on day 1 of each 14 day cycle.
Study: NCT04981223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExactVu
Description: clinical micro-ultrasound, imaging Device, Manufacturer; Exact Imaging
Study: NCT04981925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR treatment
Description: Participants will complete pre-treatment surveys followed by 8-weekly 2-hour group sessions and one 4-hour retreat (may take place virtually or in-person). Participants will also be asked to practice daily formal mindfulness at home using assigned audio recordings of 30-45 minute guided mindfulness exercises. Participants will complete surveys during treatment as well as after treatment and then at 2 months follow-up.
Study: NCT04730804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: ALXN1830 will be administered as SC infusion(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: ALXN1830 will be administered as SC infusion(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: ALXN1830 will be administered as SC infusion(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: ALXN1830 will be administered as SC infusion(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: ALXN1830 will be administered as SC infusion(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: ALXN1830 will be administered as SC infusion(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as SC infusion(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as SC infusion(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as SC infusion(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as SC infusion(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as SC infusion(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as SC infusion(s).
Study: NCT06326411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NST-628
Description: NST-628 is a small molecule non-covalent pan-RAF/MEK dual molecular glue targeting RAF and MEK nodes of MAPK pathway.
Study: NCT06286202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation: Adapted Neuropsychological and Education Approach to Remediation (NEAR)
Description: NEAR consists of computer-assisted cognitive exercises to restore cognitive functioning through rehearsal and strategy learning. Based on the results of the baseline assessments, the therapist will complete the Cognitive Remediation Treatment Plan, to outline targeted cognitive domains and functional goals. During the cognitive games sessions, the Multicontext Treatment Approach will be used, where error patterns are identified. The participants will work on metacognition and use of strategies to overcome challenges faced during the computer games sessions. Bridging groups may include activities for participants to utilize strategies learnt during the computer game sessions to everyday living. Participants will also learn about cognitive impairments and how lifestyle modifications, mood regulation etc can affect cognitive performance. In addition, they will learn about metamotivation and build awareness about their motivation levels through self- reflection and self-monitoring.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Psychiatric Rehabilitation at Anglican Care Centers
Description: Participants in the control arm will attend their usual psychiatric rehabilitation activities. These activities may include vocational training, community living skills training, psychoeducation, social skills training and peer support etc. These activities are also undertaken by participants in the experimental arm.
Study: NCT04856358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3121
Description: GLPG3121 modified-release tablet
Study: NCT04497922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: e-ink screen
Description: A virtual display screen developed by e-ink that displays patient status, basic demographics, care team information, pending tests and anticipated disposition

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual in the emergency department with communication of testing results, imaging and disposition by the primary clinical emergency department team.
Study: NCT04980443

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CELTiC test
Description: The CELTiC test is a blood-based test consisting of four mRNA markers and the risk factor age.
Study: NCT05216887

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aducanumab
Description: Administered as specified in the treatment arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aducanumab
Description: Administered as specified in the treatment arm.
Study: NCT04992182

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.3 mL IM saline solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated vaccine booster
Description: 0.5 mL IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA vaccine booster
Description: 0.3 mL IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viral vector vaccine booster
Description: 0.5 mL IM
Study: NCT04856358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3121
Description: GLPG3121 modified-release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3121
Description: GLPG3121 modified-release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3121
Description: GLPG3121 modified-release tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT06206564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate ointment
Description: Four 5-day cycles of artesunate ointment given at weeks 0, 2, 4, 6

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four 5-day cycles of placebo ointment given at weeks 0, 2, 4, 6
Study: NCT01052727

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic Cholecystectomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic Cholecystectomy
Study: NCT04953858

Intervention type: OTHER
Group type: OTHER
Intervention: Social network strategy (SNS)
Description: SNS utilizes peers to reach and recruit their network members into HIV services, therefore having the advantage that recruiters with different behavioral risks and HIV statuses are likely to have access to a wide variety of HIV at risk populations
Study: NCT05360004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine
Description: CHM is in the form of granules (9 g/sachet), which is comprised of 10 commonly used medicinal herbs: Codonopsis Radix, Astragali Radix, Lonicerae Japonicae Flos, Saposhnikovia Radix, Schizonepetae Herba, Mori Folium, Poria, Atractylodis Rhizoma, Atractylodis Macrocephala Rhizoma, Glycyrrhizae Radix et Rhizoma.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chinese herbal medicine
Description: CHM is in the form of granules (9 g/sachet), which is comprised of 10 commonly used medicinal herbs: Codonopsis Radix, Astragali Radix, Lonicerae Japonicae Flos, Saposhnikovia Radix, Schizonepetae Herba, Mori Folium, Poria, Atractylodis Rhizoma, Atractylodis Macrocephala Rhizoma, Glycyrrhizae Radix et Rhizoma.
Study: NCT05381610

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peristeen
Description: The Peristeen system will be handled by Coloplast trained personnel. The investigator and a trained nurse will participate in all the investigation related procedures. The nurse is trained in the handling of the investi-gational product as well as this is described in detail in the Instruction for Use (IFU). Subjects (and their caregivers, if appropriate) will also be trained on the use of Peristeen prior to independent use at home.
Study: NCT05514782

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cleansing Lotion
Description: Facial cleansing lotion to be used by study participants (morning and evening, 2x daily).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cleansing Lotion
Description: Facial cleansing lotion to be used by study participants (morning and evening, 2x daily).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facial Moisturizer
Description: Anti-aging facial moisturizer to be used by study participants after anti-aging daily serum before sunscreen.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Facial Moisturizer
Description: Anti-aging facial moisturizer to be used by study participants after anti-aging daily serum before sunscreen.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen SPF 40+
Description: Sunscreen to be applied after application of the facial moisturizer in the morning. Participants were asked to reapply every 2 hours.~Per FDA this intervention is an Over the counter

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sunscreen SPF 40+
Description: Sunscreen to be applied after application of the facial moisturizer in the morning. Participants were asked to reapply every 2 hours.~Per FDA this intervention is an Over the counter
Study: NCT05590884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopiclenol
Description: Patients will receive a single dose of gadopiclenol calculated according to their BW on the day of MRI examination. Gadopiclenol will be administered at a dose of 0.05 mmol/kg BW (0.1 mL/kg BW).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopiclenol
Description: Patients will receive a single dose of gadopiclenol calculated according to their BW on the day of MRI examination. Gadopiclenol will be administered at a dose of 0.05 mmol/kg BW (0.1 mL/kg BW).
Study: NCT06025773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg
Description: AD-2121 (Lansoprazole 15 mg), Oral, Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg
Description: AD-2121 (Lansoprazole 15 mg), Oral, Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15mg/Calcium carbonate 600mg
Description: AD-212-A (Lansoprazole 15mg/Calcium carbonate 600mg), Oral, Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15mg/Calcium carbonate 600mg
Description: AD-212-A (Lansoprazole 15mg/Calcium carbonate 600mg), Oral, Tablet
Study: NCT05590884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopiclenol
Description: Patients will receive a single dose of gadopiclenol calculated according to their BW on the day of MRI examination. Gadopiclenol will be administered at a dose of 0.05 mmol/kg BW (0.1 mL/kg BW).
Study: NCT04600193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet containing organic phosphate
Description: The patients will be receiving a 5 days diet containing organic phosphate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet containing inorganic phosphate
Description: The patients will be receiving a 5 days diet containing inorganic phosphate
Study: NCT06497842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-effort resistance exercise training
Description: Six sets per exercise, 8 repetitions per set.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-effort resistance exercise training
Description: Three sets per exercise, 4 repetitions per set.
Study: NCT05663606

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Happy Bob
Description: Application, which gives stars when subject reachs Time In Range

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CGM
Description: Dexcom CGM

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CGM
Description: Dexcom CGM
Study: NCT04639245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD1 Inhibitor
Description: Given IV
Study: NCT05530252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral biological antimicrobial gel
Description: The patients were divided into subgingival scaling, and Oral Biological Antimicrobial Gel was used in the periodontal pocket after scaling. The injection probe with gel was inserted into the periodontal pocket, and the injection was slowly pushed, and the injection was gradually withdrawn during the injection, until a little gel was found at the mouth of the bag.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minocycline hydrochloride ointment
Description: The patients were divided into subgingival scaling, and minocycline hydrochloride ointment was used in the periodontal pocket after scaling. The injection probe with gel was inserted into the periodontal pocket, and the injection was slowly pushed, and the injection was gradually withdrawn during the injection, until a little gel was found at the mouth of the bag.

Intervention type: OTHER
Group type: OTHER
Intervention: SRP
Description: only scaling and root planning was performed on the patient
Study: NCT06292286

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carboplatin or cisplatin
Description: Carboplatin of cisplatin for 3-6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar
Description: Paclitaxel, gemcitabine or liposomal doxorubicin, for 3-6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab or biosimilar
Description: Optional

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Description: Cytoreductive surgery after chemotherapy
Study: NCT06473857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental health literacy intervention
Description: Online interventions for adolescents and young adults on mental health literacy, 3 modalities : webconferences, build battle, serious games

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Non mental health intervention
Description: Online interventions for adolescents and young adults on other topics, 3 modalities : webconferences, build battle, serious games
Study: NCT05511233

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: feeding with breastmilk within 48 hours after surgery
Description: Electronic health records of babies who feed and not fed with breastmilk within 48 hours after surgery
Study: NCT06598085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery
Description: Surgery with the Cornerstone Surgical Robot.
Study: NCT05955794

Intervention type: OTHER
Group type: OTHER
Intervention: voice recordings
Description: Experimental treatment/procedure:~The first recording will be made in the laboratory. The lab will have sound insulation (the sound-to-noise ratio of the room should be at least 30dB) to record the voice samples. Similar to the recordings made in the lab, parents/caregivers will be instructed on how to collect voice recordings at home several times during the day using a smartphone. Parents/caregivers will be asked to note down the patient's emotional state during each recording in a predefined protocol.~All patients will undergo paediatric, morphological, neurocognitive and behavioural assessment, hearing and ENT evaluation, perceptual and acoustic voice analysis.~Perceptual assessment will be done blind.The vowel recordings will be analysed by two software tools: Biovoice \[1\] and Praat \[2\].

Intervention type: OTHER
Group type: OTHER
Intervention: voice recordings
Description: Experimental treatment/procedure:~The first recording will be made in the laboratory. The lab will have sound insulation (the sound-to-noise ratio of the room should be at least 30dB) to record the voice samples. Similar to the recordings made in the lab, parents/caregivers will be instructed on how to collect voice recordings at home several times during the day using a smartphone. Parents/caregivers will be asked to note down the patient's emotional state during each recording in a predefined protocol.~All patients will undergo paediatric, morphological, neurocognitive and behavioural assessment, hearing and ENT evaluation, perceptual and acoustic voice analysis.~Perceptual assessment will be done blind.The vowel recordings will be analysed by two software tools: Biovoice \[1\] and Praat \[2\].
Study: NCT04234477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta-blocker strategy
Description: Clinicians within the intervention groups will be free to use whatever dosing amount and frequency of their assigned medication class that they deem as medically appropriate, including the decision to use intermittent IV boluses versus continuous infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker strategy
Description: Clinicians within the intervention groups will be free to use whatever dosing amount and frequency of their assigned medication class that they deem as medically appropriate, including the decision to use intermittent IV boluses versus continuous infusions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician preference strategy
Description: This strategy allows for usual care, with providers selecting their preferred rate-control agent. IV beta-blockers available through the inpatient pharmacy include metoprolol or esmolol, and IV calcium channel blockers include diltiazem and verapamil.
Study: NCT06429917

Intervention type: OTHER
Group type: OTHER
Intervention: Subgingival instrumentation
Description: All the participants will undergo subgingival instrumentation with hand scalers, curettes and ultrasonic scaler. Parameters will be recorded at baseline and two, three and six months of time points after subgingival instrumentation.
Study: NCT04948645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosigotifator
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosigotifator
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosigotifator
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT05306873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Stage 2 Dosing:~Week 1: Participants will receive 500mg MMF/Placebo twice daily~Week 2: Participants will receive 500mg/Placebo in the morning and 1,000mg MMF/Placebo in the evening~Weeks 3-48: Participants will receive 1000mg MMF/Placebo twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Mycophenolate Mofetil
Description: Stage 2 Dosing:~Week 1: Participants will receive 500mg MMF/Placebo twice daily Week 2: Participants will receive 500mg/Placebo in the morning and 1,000mg MMF/Placebo in the evening Weeks 3-48: Participants will receive 1000mg MMF/Placebo twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voclosporin
Description: Weeks 1-24: 23.7 mg Voclosporin (3 x 7.9 capsules) twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Voclosporin
Description: Weeks 1-24: 23.7 mg Placebo for Voclosporin (3 x 7.9 capsules) twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Stage 3 Dosing:~Participants who received placebo MMF in Stage 2:~* Week 1: Participants will receive 500mg MMF plus matching placebo for MMF (to appear like a 1000mg dose) twice daily~* Week 2: Participants will receive 500mg plus matching placebo for MMF (to appear like a 1000mg dose) and 1000mg in divided doses~* Weeks 3-24: 1000mg MMF twice daily~Participants who received MMF in Stage 2~• Week 1-24: 1000mg MMF twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Stage 3 Dosing:~Participants who received placebo MMF in Stage 2:~* Week 1: Participants will receive 500mg MMF plus matching placebo for MMF (to appear like a 1000mg dose) twice daily~* Week 2: Participants will receive 500mg plus matching placebo for MMF (to appear like a 1000mg dose) and 1000mg in divided doses~* Weeks 3-24: 1000mg MMF twice daily~Participants who received MMF in Stage 2~• Week 1-24: 1000mg MMF twice daily
Study: NCT05534165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecovirimat
Description: 600 mg po BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical placebo 600 mg po BID
Study: NCT05630924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SI! Program-NYC
Description: SI! Program-NYC incorporates a comprehensive and integrated vision of CV health promotion that encompasses four (4) basic and interrelated components: body and heart, physical activity healthy diet; and emotional management.
Study: NCT05030337

Intervention type: DEVICE
Group type: OTHER
Intervention: Closed-loop automated oxygen control (Oxygenie, SLE 6000)
Description: The OxyGenie closed-loop oxygen saturation monitoring software (SLE) uses oxygen saturations from the SpO2 probe attached to the neonate, fed into an algorithm, to automatically adjust the percentage of inspired oxygen to maintain oxygen saturations within the target range. Manual adjustments including the percentage of FiO2 will be allowed at any point during the study if deemed appropriate by the clinical team.